reviewed april 2026|next review october 2026|88 physicians psi has verified|6 published studies
Copeptin
Copeptin is the 39-amino-acid C-terminal fragment of the vasopressin precursor (pre-provasopressin), released in equimolar amounts with vasopressin but far more stable in plasma, serving exclusively as a diagnostic biomarker for vasopressin system activation with no known biological function of its own.
Evidence landscape: 6 published studies
Published studies indexed under this compound. Copeptin as a biomarker is well established in the emergency medicine and endocrinology literature.
- 5 Animal
- 1 Reviews
Copeptin is not a therapeutic agent. CE-marked immunoassay (BRAHMS Copeptin) is available in Europe for clinical diagnostics. FDA clearance for copeptin assays in the United States has not been granted.
Copeptin testing is available in hospital laboratories, particularly in Europe. Less widely available in the United States. This is a blood test, not a drug or supplement.
A pure biomarker with no therapeutic application. Copeptin has no known biological function of its own. Its clinical value derives entirely from being a stable, easily measured surrogate for vasopressin, which degrades too rapidly (5-20 minute half-life) for reliable measurement.
PSI Assessment
Vasopressin is one of the most important stress hormones in the body, but it degrades so rapidly in blood samples that measuring it accurately is notoriously difficult. Copeptin solves this problem. It is released from the same precursor molecule in equimolar amounts with vasopressin but remains stable for hours in plasma, making it a reliable proxy for vasopressin system activation. The most impactful application is in emergency medicine: a single copeptin plus troponin measurement at presentation can rule out a heart attack within one hour, potentially saving hours of observation time and hospital resources.
Stable vasopressin surrogate biomarker. Combined with troponin, enables one-hour heart attack rule-out. Also replacing the water deprivation test for diabetes insipidus diagnosis.
Copeptin has no biological activity of its own. Its clinical value is entirely as a measurement tool. Vasopressin (also called ADH, antidiuretic hormone) is released from the posterior pituitary in response to osmotic stress, hemodynamic shock, or illness. Because vasopressin is unstable in blood samples, measuring copeptin provides a stable window into what the vasopressin system is doing. The dual-marker protocol (copeptin plus troponin at presentation) achieves a negative predictive value exceeding 99% for ruling out acute myocardial infarction.
What the evidence supports
Copeptin combined with troponin at presentation achieves a negative predictive value exceeding 99% for acute myocardial infarction, enabling safe early discharge from the emergency department. Stimulated copeptin differentiates central diabetes insipidus from primary polydipsia with greater accuracy than the traditional water deprivation test. Copeptin levels predict mortality in sepsis and critical illness. The immunoassay is standardized and commercially available (BRAHMS Copeptin).
What is not yet established
Whether copeptin-guided emergency department protocols improve patient outcomes compared to troponin-only strategies across all healthcare settings. Universal adoption over the water deprivation test for diabetes insipidus diagnosis. Cost-effectiveness analysis across different healthcare systems. FDA clearance for copeptin assays in the United States.
Research Evidence
The findings below cover the validated diagnostic applications and the ongoing clinical adoption of copeptin testing.
Evidence by condition
Evidence dimensions across copeptin's diagnostic applications. MI rule-out has the deepest clinical validation with large multicenter studies. Diabetes insipidus diagnosis and sepsis prognosis have supporting clinical data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| MI Rule-Out | ||||
| Diabetes Insipidus | ||||
| Sepsis Prognosis | ||||
| Stress Response |
Combining copeptin with a single troponin measurement at emergency department presentation achieves a negative predictive value exceeding 99% for acute myocardial infarction. This dual-marker approach can safely identify low-risk patients for early discharge within one hour.
The protocol has been validated in multiple large European studies. Whether it offers advantages over modern high-sensitivity troponin-only protocols in all settings remains debated. Copeptin adds cost but may reduce length of stay.
Stimulated copeptin (measured after hypertonic saline infusion) differentiates central diabetes insipidus from primary polydipsia with greater accuracy than the traditional water deprivation test, which is uncomfortable and less reliable.
The hypertonic saline stimulation test still requires medical supervision. Baseline copeptin alone is less reliable than stimulated copeptin for this diagnostic distinction.
Copeptin levels predict mortality and disease severity in critically ill and septic patients, adding prognostic value beyond traditional markers like lactate and procalcitonin.
Elevated copeptin in critical illness reflects the vasopressin stress response. Whether copeptin-guided management protocols for sepsis would improve outcomes has not been tested.
0 Human|5 Animal|1 Reviews
View all 6 indexed studiesHow Copeptin Works
Copeptin is not a drug or treatment. It is a fragment of the same precursor molecule that produces vasopressin (the body's water-retention hormone). When the pituitary gland releases vasopressin in response to stress, copeptin is released alongside it. Because copeptin stays stable in a blood sample while vasopressin degrades within minutes, doctors can use copeptin as a reliable stand-in measurement for vasopressin activity.
When the body is under stress from dehydration, low blood pressure, or a heart attack, the pituitary releases vasopressin to conserve water and raise blood pressure. Copeptin is released at the same time but is much easier to measure in a blood test. Doctors use copeptin as a proxy to understand what vasopressin is doing.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Copeptin is a 39-amino-acid glycopeptide comprising the C-terminal portion of pre-provasopressin. It is co-secreted in equimolar amounts with arginine vasopressin (AVP) from the posterior pituitary in response to osmotic and hemodynamic stimuli. Unlike AVP (half-life 5-20 minutes, platelet binding, ex vivo instability), copeptin is stable for hours in plasma at room temperature, does not bind to platelets, and can be measured by standard sandwich immunoassay (BRAHMS Copeptin, Thermo Fisher). No biological receptor or physiological function has been identified for copeptin itself.
What is Copeptin being studied for?
Researchers are studying Copeptin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Copeptin overall. This means a compound can have human studies for one condition but only animal data for another.
MI Rule-Out
·Human TrialsCopeptin combined with troponin at emergency department presentation enables a one-hour myocardial infarction rule-out protocol with a negative predictive value exceeding 99%.
Limitations: Not universally adopted. Whether copeptin adds value beyond high-sensitivity troponin-only protocols is debated. Availability varies by region (more common in Europe). Adds testing cost.
Diabetes Insipidus
·Human TrialsStimulated copeptin differentiates central diabetes insipidus from primary polydipsia with greater accuracy and less patient discomfort than the traditional water deprivation test.
Limitations: The hypertonic saline stimulation test still requires medical supervision. Baseline copeptin alone is less reliable than stimulated copeptin for this diagnostic application.
Sepsis Prognosis
·Animal StudiesElevated copeptin levels predict mortality and disease severity in critically ill and septic patients.
Limitations: Prognostic value is established but copeptin-guided management protocols for sepsis have not been developed or tested.
Stress Response
·Animal StudiesCopeptin levels reflect vasopressin system activation in response to physiological stress, including surgery, trauma, and exercise.
Limitations: The stress-response measurement is a research tool rather than a clinical application with established management implications.
Safety and Regulatory Status
FDA Status: Copeptin is not a therapeutic agent. CE-marked immunoassays are available in Europe. FDA clearance for copeptin assays in the United States has not been granted.
Availability: Available as a blood test in hospital laboratories, primarily in Europe. Not a drug or supplement. No safety concerns because copeptin testing is a standard blood draw.
Class context: A diagnostic biomarker, not a therapeutic. The only safety consideration is the standard blood draw procedure. Copeptin is never administered to patients.
Copeptin testing involves a standard blood draw with no safety concerns. It is a diagnostic biomarker, not a therapeutic. No copeptin-based drug exists or is in development. The safety profile is that of a routine laboratory test.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Copeptin discussion.
Comparison and Related Research
Copeptin is compared with other cardiovascular and stress biomarkers.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Developed and validated the first immunoassay for measuring copeptin in human blood. Because vasopressin itself is unstable and difficult to measure, copeptin (which is released in equimolar amounts from the same precursor molecule) serves as a reliable surrogate marker. This technical advance enabled all subsequent clinical studies of copeptin as a diagnostic biomarker.Morgenthaler NG et al., 2006 in Clin Chem. View on PubMed
- 2.Evaluated copeptin as an addition to troponin testing for ruling out heart attacks in the emergency department. Combining copeptin with a single troponin measurement at presentation achieved a negative predictive value above 99%, allowing safe early discharge of patients without a heart attack. This dual-marker approach could potentially spare hours of observation time.Reichlin T et al., 2009 in J Am Coll Cardiol. View on PubMed
- 3.Measured copeptin levels in patients presenting with acute stroke. Elevated copeptin concentrations at admission predicted poor functional outcomes and mortality in both hemorrhagic and ischemic stroke, positioning copeptin as a prognostic biomarker in cerebrovascular emergencies.Katan M et al., 2015 in J Clin Endocrinol Metab. View on PubMed
- 4.Large multicenter trial validating the copeptin/troponin dual-marker strategy for early myocardial infarction rule-out. The BIC-8 study demonstrated that low copeptin plus low troponin at a single time point safely identified patients who could be discharged from the emergency department without extended monitoring or serial blood draws.Mockel M et al., 2018 in BMJ. View on PubMed
- 5.Evaluated copeptin as a diagnostic tool for distinguishing between different causes of low blood sodium. Because copeptin reflects vasopressin secretion, measuring it helped clinicians differentiate between inappropriate vasopressin secretion (SIADH), volume depletion, and other etiologies, potentially simplifying a diagnostic workup that traditionally requires complex testing.Fenske W et al., 2012 in J Clin Endocrinol Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.